Shanghai, China · Founded 2020 · In IPO Registration
Developer and manufacturer of CAR-T cell therapies and innovative treatment platforms designed for solid tumors and hematological cancers. Immunofoco Biotechnology is based in Shanghai, China and was founded in 2020. Its last reported valuation was $298 million in Feb 2026. It has raised $139 million.
Last reported valuation
$298.1M
Oct 2026
Priced at
—
Total raised
$138.8M
Last round
—
Cap table — not yet on record
Immunofoco Biotechnology's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Immunofoco Biotechnology with a free account
·The complete investor list: 27 names
·Watch Immunofoco Biotechnology: the Monday email on marks, rounds and moves
